Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:42:27.413Z.
Calculation as of: 2026-10-06T15:42:27.413Z.
Quote observation: 2026-10-06T15:40:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 770a25882bbf240e7dd0e921658fc1146ed3cbaaf52ff006066619216260c690
PEG RATIO
N/A
Kiniksa Pharmaceuticals International, plc
Market Cap
$5.82B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.03B
PEG Ratio
N/A
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.06
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | $5.82B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.85B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | N/A | N/A | N/A | N/A |
| GRAIL Inc. (GRAL)vs › | $6.02B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.03B | N/A | 0.03 | 0.06 | 0.06 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.55B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.43B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.37B | 0.65 | 0.43 | 0.41 | 0.41 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.27B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.27B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
77.9
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
